Search Results
Aug 26, 2025, 10:00 ET QCY présente ses écouteurs sans fil MeloBuds N70 ANC pour une expérience sonore quotidienne plus intelligente
Photo - https://mma.prnewswire.com/media/2755094/Picture__HT18.jpg Logo - https://mma.prnewswire.com/media/2415696/QCY_LOGO_Logo.jpg
More news about: QCY
Aug 26, 2025, 04:08 ET Hisense Captures the Global Spotlight with Six EISA Awards for Image and Sound Excellence
Mini Projector and the PX3-PRO Laser Cinema, which impressed with their versatility and cinematic quality. Hisense also received recognition for its HT Saturn Wireless Surround System, celebrated for its immersive sound powered by Devialet. These achievements reinforce Hisense's dedication to
More news about: Hisense Middle East
Aug 26, 2025, 04:06 ET Hisense Captures the Global Spotlight with Six EISA Awards for Image and Sound Excellence
Mini Projector and the PX3-PRO Laser Cinema, which impressed with their versatility and cinematic quality. Hisense also received recognition for its HT Saturn Wireless Surround System, celebrated for its immersive sound powered by Devialet. These achievements reinforce Hisense's dedication to
More news about: Hisense Middle East
Aug 25, 2025, 13:04 ET Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research
a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive
More news about: Human Longevity, Inc.
Aug 25, 2025, 10:01 ET Single Cell Sequencing Market worth $3.46 billion by 2030 with 12.2% CAGR | MarketsandMarkets™
February 2025, the IDIBAPS research institute (Clínic Barcelona) incorporated the BD Rhapsody HT Single-Cell Analysis System into its Functional Genomics Platform. This high-throughput system, featuring microwell-based cell isolation and eight-lane
More news about: MarketsandMarkets
Aug 25, 2025, 08:59 ET AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Phase 2 development for the treatment of major depressive disorder (MDD).Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.NORTH CHICAGO, Ill. and NEW
More news about: AbbVie
Aug 25, 2025, 03:32 ET Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
WEST10 About Bexicaserin Bexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risks of cardiovascular toxicity associated with nonselective serotonergic
More news about: H. Lundbeck A/S
Aug 25, 2025, 03:26 ET Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
WEST10 About Bexicaserin Bexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risks of cardiovascular toxicity associated with nonselective serotonergic
More news about: H. Lundbeck A/S
Aug 19, 2025, 08:47 ET HT Materials Science Delivers Substantial Energy Savings for DKSH Malaysia
DUBLIN, Aug. 19, 2025 /PRNewswire/ -- HT Materials Science (HTMS), a global leader in cooling technology, has successfully implemented its breakthrough heat-transfer fluid, Maxwell®, at a pharmaceutical
More news about: HT Materials Science
Aug 19, 2025, 08:30 ET HT Materials Science Delivers Substantial Energy Savings for DKSH Malaysia
DUBLIN, Aug. 19, 2025 /PRNewswire/ -- HT Materials Science (HTMS), a global leader in cooling technology, has successfully implemented its breakthrough heat-transfer fluid, Maxwell®, at a pharmaceutical
More news about: HT Materials Science
Aug 03, 2025, 06:23 ET 綠葉製藥靶向NET/DAT/GABAAR的抗抑鬱1類創新藥完成I期臨床 首例受試者入組
包括抑鬱症在內的CNS治療領域患者需求龐大，但新藥研發進展相對較緩。圍繞該領域，綠葉製藥已在中國、美國、歐洲、日本等市場獲批一系列具有國際競爭力的創新藥和創新制劑，包括：ErzofriR（棕櫚酸帕利哌酮緩釋混懸注射液）、RykindoR（利培酮緩釋微球注射劑）已在美國獲批上市，利斯的明透皮貼劑（2次/W）已在歐洲多國、日本、中國獲批上市，若欣林R（鹽酸托魯地文拉法辛緩釋片）、金悠平R（注射用羅替高汀微球）已在中國獲批上市等。同時，公司積極佈局下一代創新藥的研發，另有TAAR1/5-HT2CR雙靶點新藥LY03020、VMAT2/Sigma-1雙靶點新藥LY03015、5-HT2AR/5-HT2CR雙靶點新藥LY03017等多個1類創新藥處於臨床階段。
More news about: 綠葉製藥
Jul 31, 2025, 16:05 ET MATSON, INC. ANNOUNCES SECOND QUARTER 2025 RESULTS
Time: 4:30 p.m. ET / 1:30 p.m. PT / 10:30 a.m. HT The conference call will be broadcast live along with an additional slide presentation on the Company's website at www.matson.com,
More news about: Matson, Inc.
Jul 30, 2025, 09:46 ET Alamar Biosciences spolupracuje s Německým centrem pro neurodegenerativní onemocnění (DZNE) na průlomovém proteomickém profilování v kohortě Studie Porýní
oblasti přírodních věd, která si za své poslání zvolila přesnou proteomiku pro včasnou detekci onemocnění. Její proprietární platforma NULISA a systém ARGO HT perfektně spolupracují s nejnovějšími pokroky v genomice a dosahují detekční citlivosti v řádu attomolů, což výrazně předčí nejcitlivější technologie
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 09:01 ET Alamar Biosciences и Немецкий центр нейродегенеративных заболеваний (DZNE) совместно проводят знаковое исследование по протеотомному профилированию в когортном исследовании Rhineland Study
возможности использовать прецизионную протеомику для ранней диагностики заболеваний. Запатентованная компанией платформа NULISA, а также система ARGO HT System безупречно взаимодействует с новейшими разработками в области геномики, обеспечивая чувствительность обнаружения на аттомолярном уровне, значительно
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 08:57 ET Alamar Biosciences dan German Center for Neurodegenerative Diseases (DZNE) bermitra untuk penelitian Landmark Proteomic Profiling dalam Kelompok Rhineland Study
hayati dengan misi untuk mendukung proteomik presisi yang memungkinkan deteksi penyakit lebih dini. Platform NULISA milik Alamar Biosciences bersama ARGO HT System bekerja tanpa kendala dengan kemajuan terbaru di bidang genomik untuk mencapai sensitivitas deteksi attomolar satu digit, jauh melampaui teknologi
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 22:09 ET Alamar Biosciences et le Centre allemand pour les maladies neurodégénératives (DZNE) s'associent pour une étude historique de profilage protéomique dans la cohorte d'étude rhénane
consiste à développer la protéomique de précision afin de permettre la détection précoce des maladies. La plateforme propriétaire NULISA et le système ARGO HT s'intègrent parfaitement aux dernières avancées de la génomique pour atteindre une sensibilité de détection attomolaire à un chiffre, dépassant largement
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 15:20 ET Alamar Biosciences und das Deutsche Zentrum für Neurodegenerative Erkrankungen (DZNE) arbeiten an wegweisender Proteomic-Profiling-Studie in Kohorte der Rheinland-Studie zusammen
die Präzisionsproteomik voranzutreiben, um die frühestmögliche Erkennung von Krankheiten zu ermöglichen. Die firmeneigene NULISA Platform und das ARGO HT System greifen nahtlos mit den neuesten Fortschritten in der Genomik ineinander, um eine Nachweisempfindlichkeit im einstelligen Attomolbereich zu erreichen,
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 14:43 ET Spoločnosť Alamar Biosciences a Nemecké centrum pre neurodegeneratívne ochorenia (DZNE) spolupracujú na štúdii pre významné proteomické profilovanie v kohorte štúdie Porýnia
poslaním je podporovať presnú proteomiku s cieľom odhaľovať choroby čo najskôr. Vlastná platforma spoločnosti s názvom NULISA spolu so systémom ARGO HT bezproblémovo spolupracujú s najnovšími pokrokmi v genomike, aby sa dosiahla jednociferná citlivosť atomolárnej detekcie, čím sa výrazne prekonáva najcitlivejšia
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 11:50 ET Alamar Biosciences 與德國神經退化性疾病中心 (DZNE) 合作，在萊茵蘭研究群體中進行具里程碑意義的蛋白質體學分析研究
www.rheinland-studie.de/en/ 關於 Alamar Biosciences, Inc. Alamar Biosciences 是一間私營生命科學公司，以驅動精準蛋白質體來實現最早疾病檢測為使命。該公司的專利 NULISA Platform 與 ARGO HT System 無縫合作，推動最新基因組學發展，並達至單位數阿摩爾偵測靈敏度，大幅超越目前市面最靈敏的蛋白質偵測科技。如欲更多資料，請瀏覽
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 11:34 ET Alamar Biosciences i Niemiecki Ośrodek Chorób Neurodegeneracyjnych (DZNE) rozpoczynają współpracę nad przełomowym badaniem proteomicznym w kohorcie badania Rhineland
tworzenie rozwiązań na potrzeby proteomiki ukierunkowanej w celu jak najwcześniejszego wykrywania chorób. Jej autorska platforma NULISA oraz system ARGO HT bazują na aktualnej wiedzy w obszarze genomiki, zapewniając czułość detekcyjną na poziomie jednocyfrowych stężeń atomolowych, a więc znacznie wyższą
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET 알라마 바이오사이언스, 독일 신경퇴행성질환센터(DZNE)와 파트너십 체결 - 라인란트 연구 코호트에서 대규모 단백질체 분석 연구 착수
알라마 바이오사이언스(Alamar Biosciences, Inc.) 소개 알라마 바이오사이언스는 질병의 조기 발견을 위한 정밀 단백질체학 솔루션을 제공하는 비상장 생명과학 기업이다. 알라마의 독점적인 NULISA™ 플랫폼과 ARGO™ HT 시스템은 최신 유전체학 솔루션들과 완벽하게 호환되어 한 자릿수의 아토몰(attomolar) 검출 감도를 제공하며 현재 출시된 다른 고감도 단백질 검출 기술들을 크게 능가한다. 자세한 내용은
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET Alamar Biosciences y el DZNE se asocian para un estudio de perfil proteómico
es impulsar la proteómica de precisión para la detección temprana de enfermedades. Su plataforma NULISA, propiedad de la compañía, y el sistema ARGO HT se integran a la perfección con los últimos avances en genómica para lograr una sensibilidad de detección atomolar de un solo dígito, superando ampliamente
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 07:58 ET Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
international clinical development strategy for HT-001. The trial is currently enrolling patients in multiple sites in the United States. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities
More news about: Hoth Therapeutics, Inc.